NOX 2.86% 7.2¢ noxopharm limited

VISION (NCT03511664) is a phase 3 study designed to assess the...

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177Lu-PSMA-617 in patients with PSMA-positive mCRPC ... On active treatment, median OS is assumed to be 13.7 months with a hazard ratio (HR) of 0.7306, and rPFS is assumed to be 6 months with an HR of 0.67.

    VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). | Journal of Clinical Oncology (ascopubs.org)
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
7.2¢
Change
0.002(2.86%)
Mkt cap ! $21.04M
Open High Low Value Volume
7.2¢ 7.2¢ 7.2¢ $1.367K 18.99K

Buyers (Bids)

No. Vol. Price($)
1 72463 6.9¢
 

Sellers (Offers)

Price($) Vol. No.
7.2¢ 8810 1
View Market Depth
Last trade - 15.33pm 26/07/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.